MVRBF - Medivir posts results from investigator-initiated mid-stage carcinoma study

Medivir AB ([[MVRBF]]) announces positive results from the investigator-initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma ((SCC)).The primary objective of the study was to assess the effects of topical remetinostat on biopsy-proven SCC and SCC in situ tumors.Four patients with five cutaneous SCCs were included in the study and were treated with remetinostat gel 1%.All five tumours, including a range of histological subtypes, demonstrated complete clinical and pathological resolution after up to 8 weeks of treatment, the company said.However, all patients experienced a localized skin reaction in response to the treatment, which required one patient to discontinue therapy. No systemic adverse events were reported.

For further details see:

Medivir posts results from investigator-initiated mid-stage carcinoma study